In addition, the tyrosine kinase receptor inhibitor nintedanib, which blocks FGFR, platelet-derived growth factor receptor (PDGFR), vascular endothelial growth factor receptor (VEGFR), and Src family kinases, has been FDA approved for the treatment of pulmonary fibrosis and was found to attenuate renal fibrosis and inhibit activation of renal interstitial fibroblasts in a mouse model of renal fibrosis [44]. Here, KDR is linked to renal fibrosis.